Biotechnology

ChemPartner

ChemPartner released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 266.69 M, actual EPS CNY -0.04

ChemPartner released FY2025 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 317.87 M, actual EPS CNY 0.0217

ChemPartner released FY2025 earnings on April 28 After-Market (BJT), actual revenue CNY 1.135 B, actual EPS CNY 0.03

ChemPartner to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

ChemPartner to Release FY2025 Annual Earnings on April 29 After-Market (BJT)

Fosun Pharma and RuiZhi Pharma Sign Strategic Cooperation Framework Agreement

ChemPartner released FY2025 9 Months Earnings on October 29 During-Market BJT, actual revenue CNY 816.85 M, actual EPS CNY 0.0302

ChemPartner released FY2025 Q3 earnings on October 29 During-Market BJT, actual revenue CNY 283.05 M, actual EPS CNY -0.0363

ChemPartner to Release FY2025 Q3 Earnings on October 30 During-Market BJT

ChemPartner released FY2025 Q2 earnings on August 28 After-Market BJT, actual revenue CNY 272.54 M, actual EPS CNY 0.0565

ChemPartner released FY2025 Semi-Annual Earnings on August 28 After-Market (BJT), actual revenue CNY 533.8 M, actual EPS CNY 0.0509

ChemPartner to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

RuiZhi Pharmaceutical and KoEnTai Sign Deep Strategic Cooperation Agreement

RuiZhi Medicine Signs Strategic Cooperation Agreement with Guangzhou ConTech

RuiZhi Pharmaceutical and LiDao Pharmaceutical Sign Strategic Cooperation Agreement

RuiZhi Medicine and TianQin Bio Sign Strategic Cooperation to Build a One-Stop New Drug R&D Platform

RuiZhi Pharmaceutical Engaged in a Block Trade

Sirnaomics Enters Strategic Collaboration with Ruiyi Pharma

RuiZhi Pharmaceutical Suffers From Large Block Trading

RuiZhi Medicine and SunGen Biopharma Sign Strategic Collaboration on RNAi Drug Development

300436

601872

399006

300723

399001

300149

000001

159915

510210

ChemPartner, Cosunter, and CMES hit the daily limit up, ApicHope rose over 14%; biotechnology, shipping, and pharmaceuticals led the gains, while oil and gas, electricity, and highways saw the largest declines; the SSE Index rose 1.46%, the Shenzhen Index rose 1.7%, and the ChiNext rose 1.96%

36Kr

Cosunter

CMES

ChiNext

ApicHope

Shenzhen Index

SSE Index

E Fund GEM ETF

Fullgoal SSE Composite ETF

The three major A-share indices all closed higher

601899

688256

02899

36Kr learned that the three major A-share indices collectively rose during the midday break, with the Shanghai Composite Index up 1.36%, the Shenzhen Component Index up 1.2%, and the ChiNext Index up 1.18%. The biotechnology, semiconductor, and precious metals sectors led the gains, with ChemPartner hitting the daily limit, Cambricon rising over 6%, and Zijin Mining increasing over 3%; the forestry, aerospace and military, and power sectors saw the largest declines, with Pingtan Development dropping over 5%, Aerospace Development falling over 3%, and Xichang Electric Power decreasing over 2%

Zijin Mining

VanEck Gold Miners ETF

Cambricon

ZIJIN MINING

The three major A-share indices collectively rose during the midday break, with pharmaceutical stocks leading the gains

688796

300497

603538

301509

600721

CRO concept stocks fluctuated and strengthened, with Fushine and Menovo both hitting the daily limit, Kingchem rising more than 10%, and Biocytogen, BHC, and ChemPartner following suit

Wallstreetcn

Biocytogen

Fushine

Menovo

Kingchem

ChemPartner has unveiled a fresh visual identity that reflects their extensive scientific experience, flexible collaboration approach, and dedication to supporting innovative life science firms in speeding up the process of launching groundbreaking drugs. The company is based in both Shanghai and Watertown, Massachusetts. The announcement was made on January 1, 2026.

Unusual Whales

ChemPartner unveils updated visual identity to reflect its reputation as a trusted biopharma partner, aiming to help life science companies efficiently bring drugs to market.

ChemPartner erupted in a "palace intrigue" incident, as the 90s-born beauty host Gao Yingying resigned just 11 days after taking office as the secretary of the board, attracting industry attention. Gao Yingying was originally an employee of Hu Ruilian, the actual controller of the company, and other holding entities. Her resignation is related to the ongoing four-year struggle for control of the company. The announcement did not mention the reason for her resignation, and the outside world is full of curiosity about this matter

Stheadline

ChemPartner exploded with a "palace intrigue" battle as a post-90s beauty company secretary resigned urgently after just 11 days in office

ChemPartner announced that its revenue for the third quarter was 283 million yuan, a year-on-year increase of 11.72%; the net profit loss was 18.2908 million yuan. Revenue for the first three quarters was 817 million yuan, a year-on-year increase of 13.68%; the net profit was 7.0913 million yuan, a year-on-year increase of 111.50%

Zhitong

ChemPartner: Net loss of RMB 18.2908 million in the third quarter

ChemPartner's wholly-owned subsidiary Beihai ChemPartner has signed an agreement with Shenzhen Investment Holdings Donghai Investment and other partners to jointly invest in the establishment of Shenzhen Luohu Donghai ChemPartner Pharmaceutical Industry Partnership, with a total subscription amount of 200 million yuan, of which Beihai ChemPartner contributes 58 million yuan, accounting for 29%. The partnership will focus on investing in innovative drugs and medical devices, aiming to enhance the company's capital operation capabilities and competitiveness

ChemPartner's subsidiary plans to invest 58 million yuan in an industrial fund focusing on innovative drugs

According to the Qichacha APP, recently, Guangdong ChemPartner Investment Co., Ltd. was established with a registered capital of 10 million yuan. The business scope includes: technical consulting services for artificial intelligence public service platforms; information technology consulting services; information consulting services, etc. The equity penetration of Qichacha shows that the company is wholly owned by ChemPartner

ChemPartner establishes a new company, including AI-related businesses

According to the Zhitong Finance APP, ChemPartner released its semi-annual report for 2025, showing an operating income of 534 million yuan, a year-on-year increase of 14.75%. The net profit attributable to shareholders of the listed company was 25.3821 million yuan. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 6.7923 million yuan. The basic earnings per share were 0.051 yuan

ChemPartner released its half-year performance, turning a profit of 25.3821 million yuan

003017

300696

301511

300476

This week, 125 listed companies disclosed institutional research minutes, with nearly 40% of stocks achieving positive returns. Defu Technology and VGT rose more than 20%, while ChemPartner, DAYANG BIOTECH, ALD, and 7 other stocks rose more than 10%. The median price change of the surveyed stocks was -1.51%

DAYANG BIOTECH

Defu Technology

The research enthusiasm for star companies is high, and leading enterprises frequently release positive signals

ChemPartner(300149.SZ)